Quintiles invests in biomarker start-up; Glyn Edwards to head
This article was originally published in Scrip
Quintiles has invested £3 million in a new company formed in partnership with the University of Oxford and two of its professors, which will provide oncology consulting services and new cancer biomarkers to clients.
You may also be interested in...
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"